Menu
Sign In Search Podcasts Charts Entities Add Podcast API Pricing
Podcast Image

4-Quarter Lives

Tina Backhouse: Straight Talk on Women’s Health in Q3

09 Oct 2024

Description

This week on 4-Quarter Lives, Avivah Wittenberg-Cox talks with Tina Backhouse, the General Manager in the UK of Theramex, a global speciality pharmaceutical company focused on supporting the health needs of women at all stages of life. They discuss the particular health needs of women, particularly as they age, the need for women to monitor key health metrics post menopause, the specific risks of cardiovascular disease, dementia and osteoporosis and the need for research to take better account of different ethnicities and age groups. Tina describes how Theramex addresses these and other health issues, the changing health concerns for women pre- and post-menopause, the value of DEXA scans, other preventative screenings and the increased importance of fitness, diet and exercise habits from the late 40s onwards. They discuss the role of supplements and of HRT treatment. Tina Backhouse has over 25 years’ experience in global senior leadership roles in the pharmaceutical industry, launching innovative products across a diverse range of therapy areas in both large and small pharma companies. She joined Theramex to lead the UK Women’s Health business in 2020, helping establish Theramex in the UK as the largest supplier of HRT & Menopause Products. She is passionate about there being equality of healthcare for all women in the UK, and that women have choice in their healthcare options. Some Useful Links: * Theramex UK website * Theramex International website * The British Menopause Society website  Get full access to Elderberries at elderberries.substack.com/subscribe

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

No transcription available yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.